SCHEMBL6492376

SCHEMBL6492376

CC1CC2CCN1C[C@@H]2NC(=O)c1ccc(-c2ccccc2F)o1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.48
NPC1 O15118 4/20 0.48
OPRM1 P35372 1/20 0.48
OPRD1 P41143 1/20 0.48
SMN1; SMN2 Q16637 4/20 0.46
HSD17B10 Q99714 3/20 0.46
HPGD P15428 1/20 0.46
KMT2A Q03164 1/20 0.46
KDM4E B2RXH2 4/20 0.45
MAPK1 P28482 2/20 0.45
MAPT P10636 3/20 0.44
ALDH1A1 P00352 3/20 0.44
TSHR P16473 1/20 0.44
ATM Q13315 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
POLB P06746 1/20 0.42
PDE4B Q07343 4/20 0.41
CHRNA7 P36544 1/20 0.41
HTR3A P46098 1/20 0.41
MGAM O43451 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6496106 0.89 CHRNA7 (0.44) RAB9ANPC1ALDH1A1POLBCHRNA7
SCHEMBL6488495 0.89 ALDH1A1 (0.46) RAB9ANPC1HPGDKMT2AKDM4E
SCHEMBL6502115 0.88 RAB9A (0.52) RAB9ANPC1SMN1; SMN2HPGDKMT2A
SCHEMBL6632514 0.88 RAB9A (0.52) RAB9ANPC1SMN1; SMN2HPGDKMT2A
SCHEMBL6490697 0.88 CHRNA7 (0.43) RAB9ANPC1ALDH1A1POLBCHRNA7
SCHEMBL6487870 0.87 CHRNA7 (0.53) RAB9ANPC1SMN1; SMN2HSD17B10HPGD
SCHEMBL6497753 0.86 ALDH1A1 (0.52) RAB9ANPC1KMT2AKDM4EMAPT
SCHEMBL6491301 0.86 SMN1; SMN2 (0.44) RAB9ANPC1OPRM1OPRD1SMN1; SMN2
SCHEMBL6487899 0.85 ALDH1A1 (0.39) RAB9ANPC1OPRM1OPRD1SMN1; SMN2
SCHEMBL6500448 0.84 ALDH1A1 (0.52) RAB9ANPC1SMN1; SMN2HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US claimed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US claimed
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US disclosed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease MALT1, WFS1, NR5A1 RAB9A 1437/4885NPC1 224/4885OPRM1 403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.